Novartis on Tuesday signalled growing interest in selective takeovers, just as its core pharmaceuticals business suffered the most severe competition to date from cut-price generic competition.

Generic rivalry to two big selling products, and the suspension of a third on health grounds, prompted the Swiss pharmaceuticals group to revise down its sales expectations at its core drugs division this year.